|
|
Volumn 10, Issue 5, 2015, Pages e26-e27
|
|
CSF concentration of crizotinib in two ALK-positive non-small-cell lung cancer patients with CNS metastases deriving clinical benefit from treatment
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANAPLASTIC LYMPHOMA KINASE;
CERITINIB;
CRIZOTINIB;
ANTINEOPLASTIC AGENT;
PROTEIN TYROSINE KINASE;
PYRAZOLE DERIVATIVE;
PYRIDINE DERIVATIVE;
ADULT;
BRAIN DAMAGE;
CANCER CHEMOTHERAPY;
CANCER GROWTH;
CANCER PATIENT;
CANCER RADIOTHERAPY;
CARCINOMATOUS MENINGITIS;
CASE REPORT;
CENTRAL NERVOUS SYSTEM METASTASIS;
CEREBROSPINAL FLUID ANALYSIS;
CYTOLOGY;
DISEASE SEVERITY;
DRUG SUBSTITUTION;
DRUG WITHDRAWAL;
HUMAN;
MALE;
MIDDLE AGED;
NON SMALL CELL LUNG CANCER;
NOTE;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PRIORITY JOURNAL;
TREATMENT DURATION;
TREATMENT RESPONSE;
ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;
WHOLE BRAIN RADIOTHERAPY;
BLOOD;
BRAIN NEOPLASMS;
CEREBROSPINAL FLUID;
LUNG NEOPLASMS;
MENINGEAL CARCINOMATOSIS;
SECONDARY;
ADULT;
ANTINEOPLASTIC AGENTS;
BRAIN NEOPLASMS;
CARCINOMA, NON-SMALL-CELL LUNG;
HUMANS;
LUNG NEOPLASMS;
MALE;
MENINGEAL CARCINOMATOSIS;
MIDDLE AGED;
PYRAZOLES;
PYRIDINES;
RECEPTOR PROTEIN-TYROSINE KINASES;
|
|
EID: 84938269464
PISSN: 15560864
EISSN: 15561380
Source Type: Journal
DOI: 10.1097/JTO.0000000000000468 Document Type: Article |
|
Times cited : (100)
|
|
References (6)
|
